Aclaris Therapeutics, Inc.
0H8T.L
London Stock Exchange5.70
USD
+0.08
- -
Aclaris Therapeutics, Inc.
0H8T.L
(London Stock Exchange)
Recent
price
5.70
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small and large molecule drug candidates targeting immuno-inflammatory diseases through kinase inhibition and biologic innovation. Founded in 2012 and headquartered in Wayne, Pennsylvania, with additional operations in St. Louis, Missouri, the company leverages its proprietary KINect platform to explore protein kinases for small molecule inhibitors addressing chronic inflammation and autoimmune conditions; it also advances monoclonal and bispecific antibodies with dual-targeting mechanisms for validated immune pathways. Core offerings include a pipeline featuring topical and oral candidates such as ATI-1777, a soft JAK1/3 inhibitor for atopic dermatitis, ATI-2138, an oral ITK/JAK3 inhibitor for hidradenitis suppurativa, pyoderma gangrenosum and ulcerative colitis, and discovery-stage gut-restricted CAMKIIδ inhibitors for inflammatory bowel disease; the company operates Confluence Discovery Technologies, Inc., a subsidiary providing full-service drug discovery and early development as a contract research organization serving pharma and biotech across therapeutic areas. Aclaris Therapeutics primarily targets patients with unmet needs in dermatology, immunology and related fields, with global development ambitions excluding certain regions like Greater China for specific assets. Recent strategic developments include an exclusive global license agreement in November 2024 with Biosion for BSI-045B, a Phase 2 anti-TSLP monoclonal antibody for atopic dermatitis and other indications, and BSI-502, a preclinical TSLP/IL4R bispecific antibody, involving over $40 million upfront cash plus equity and up to $900 million in milestones with royalties; concurrently, the company completed an $80 million private placement led by Vivo Capital to fund pipeline advancement. These transactions expand the immunology portfolio amid 2024 pipeline prioritization following prior discontinuations and workforce restructuring, with cash runway extended into 2027 or later.